07:56 AM EST, 11/13/2025 (MT Newswires) -- Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) have entered into a partnership with Mangoceuticals ( MGRX ) to launch two integrated programs that provide direct access to the two firms' GLP-1 medications, Mangoceuticals ( MGRX ) said Thursday.

MangoRx Direct and PeachesRx Direct will provide access to Lilly's Zepbound and Novo Nordisk's ( NVO ) Wegovy, respectively, Mangoceuticals ( MGRX ) said.

Through MangoRx and PeachesRx's secure telehealth platform, customers will receive virtual consultations with board-certified providers, personalized weight management treatment plans, ongoing clinical monitoring and support, and fulfillment of the medications, the company said.